Mohammad Azam, PhD
- Member, Division of Experimental Hematology & Cancer Biology
- Professor, UC Department of Pediatrics
About
Post-doc: Whitehead Institute for Biomedical Research at MIT, 2001-2003.
Instructor: Children’s Hospital of Boston and Harvard Medical School, 2006-2009.
Interests
Leukemia
Interests
Structure and function analysis of tyrosine kinases involved in the pathogenesis of leukemia; molecular basis of "oncogene addiction" modeling of human leukemia in mice using ES and patient derived iPS cells
Research Areas
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
Publications
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Blood Advances. 2023; 7:1460-1476.
Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Advances. 2022; 6:1186-1192.
PLaCatinG AML1-ETO. Blood. 2022; 139:959-961.
Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition. Proceedings of the National Academy of Sciences of USA. 2021; 118:e2020102118.
SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling. Proteomics: Clinical Applications. 2020; 14:e1900144.
From the Blog
Research Reveals Potential Achille’s Heel in Treatment-Resistant MPN
Mohammad Azam, PhD8/21/2023
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
